Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Năm xuất bản2021

Nguồn học thuậtThe Lancet Infectious Diseases

Định danhDOI 10.1016/s1473-3099(20)30831-8

TRÍCH DẪN ĐỀ XUẤT

Shengli Xia; Yuntao Zhang; Yanxia Wang; Hui Wang; Yunkai Yang; George Fu Gao; Wenjie Tan; Guizhen Wu; Miao Xu; Zhiyong Lou; Weijin Huang; Wenbo Xu; Baoying Huang; Huijuan Wang; Wei Wang; Wei Zhang; Na Li; Zhiqiang Xie; Ling Ding; Wangyang You; Yuxiu Zhao; Xuqin Yang; Yang Liu; Qian Wang; Lili Huang; Yongli Yang; Guangxue Xu; Bojian Luo; Wenling Wang; Peipei Liu; Wanshen Guo; Xiaoming Yang (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases, 21(1), 39-51. https://doi.org/10.1016/s1473-3099(20)30831-8

Thông tin thư mục

Nguồn/Tạp chí: The Lancet Infectious Diseases
Tập: 21
Số: 1
Trang: 39-51
Nhà xuất bản: Elsevier BV
DOI: 10.1016/s1473-3099(20)30831-8 ↗

Từ khóa

Medicine; Placebo; Immunogenicity; Tolerability; Clinical trial; Randomized controlled trial; Internal medicine; Adverse effect; Immunology; Antibody